HilleVax is a biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. Its initial programme, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. Norovirus is a common intestinal infection marked by diarrhoea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration. HilleVax listed on the Nasdaq in April 2022 with the ticker: HLVX

LocationBoston, MA
CEORob Hershberg
Partner Andrew Sinclair
Websitewww.hillevax.com